HPV Vaccine: A Complete Guide to Benefits, Safety, Vaccination Schedule and Government Policies in India

The Human Papillomavirus (HPV) vaccine is an important development in preventive healthcare. It helps protect people against certain types of human papillomavirus, a common group of viruses that can affect the skin and moist tissues of the body. Some HPV types can cause health problems, including cervical cancer and other HPV-related cancers.

HPV infections are commonly transmitted through intimate skin-to-skin contact. Many infections disappear naturally because the immune system clears them. However, certain high-risk HPV infections can remain in the body for several years and gradually cause abnormal cell changes.

The HPV vaccine was developed to help prevent infections from specific virus types before exposure occurs. It works by preparing the immune system to recognise and respond to HPV.

There are different types of HPV vaccines, including:

  • Bivalent vaccines: Protect against HPV types 16 and 18, which are responsible for a large proportion of cervical cancer cases.

  • Quadrivalent vaccines: Protect against HPV types 6, 11, 16 and 18.

  • Nonavalent vaccines: Provide protection against nine HPV types, including additional high-risk strains.

The vaccine does not contain live HPV capable of causing infection. Instead, it uses virus-like particles to stimulate an immune response.

According to the World Health Organization (WHO), HPV vaccination is an important part of the global strategy to prevent cervical cancer.

Why HPV Vaccination Matters Today

HPV vaccination matters because persistent infection with certain high-risk HPV types is the leading cause of cervical cancer. Cervical cancer develops in the cervix, the lower part of the uterus.

It generally develops gradually, which makes prevention and early detection particularly important.

Protection Against Cervical Cancer

HPV vaccination can significantly reduce the risk of cervical cancer associated with the virus types included in the vaccine. Vaccination before exposure provides the greatest preventive benefit.

Protection Against Other HPV-Related Conditions

Depending on the vaccine type, immunisation can also help prevent:

  • Genital warts associated with HPV types 6 and 11.

  • Certain HPV-related cancers of the vagina and vulva.

  • Some anal cancers.

  • Certain cancers of the penis.

  • Some cancers of the throat and oropharynx.

Who Should Consider HPV Vaccination?

The primary target group for HPV vaccination is adolescents, particularly girls aged 9–14 years. Vaccination at this stage is recommended because it generally occurs before exposure to HPV.

However, eligibility and recommended schedules can vary according to age, vaccine type, medical history and national guidelines.

Boys may also benefit from HPV vaccination because the virus can cause certain cancers and genital warts in males.

Adults who have not previously received the vaccine can discuss their eligibility with a qualified healthcare professional.

Why Early Vaccination Is Important

Vaccination is preventive rather than curative. It does not remove an existing HPV infection or treat cervical cancer.

Receiving the vaccine at the recommended age helps the immune system develop protection before potential exposure. This makes adolescent immunisation an important public health priority.

HPV Vaccine Schedule, Types and Expected Protection

The HPV vaccination schedule depends on the vaccine product, age and immune status.

The following table provides a general overview of internationally recognised vaccination approaches.

Category

General vaccination guidance

Girls aged 9–14

One or two doses, depending on applicable guidance

Individuals aged 15–20

One or two doses under WHO guidance

Women above 21

Generally two doses, six months apart under the December 2022 WHO guidance

Immunocompromised individuals

At least two doses and, where possible, three doses

WHO's October 2026 update also reports strengthened recommendations for single-dose vaccination and an expanded age range up to 30 years, following a review by its Strategic Advisory Group of Experts on Immunization (SAGE). A revised formal WHO position paper is expected in 2027.

These international recommendations should not automatically be treated as the schedule for every vaccine or national programme. Individuals should follow the current guidance applicable to their circumstances.

Recent Developments in HPV Vaccination

HPV vaccination has received increased attention during the past year because governments and international health organisations are strengthening their cervical cancer prevention strategies.

Several developments are particularly relevant.

India Launches a Nationwide HPV Vaccination Campaign – February 28, 2026

The Government of India launched a nationwide HPV vaccination campaign on February 28, 2026. The initiative primarily targets approximately 1.2 crore girls aged 14 years across all 36 States and Union Territories.

The campaign uses the quadrivalent Gardasil-4 vaccine as a single-dose vaccination under the national programme. It is voluntary and requires parental or guardian consent.

Vaccination is available at designated government health facilities, including Primary Health Centres, Community Health Centres, district hospitals and government medical colleges.

India Crosses 80 Lakh Vaccinations – September 2026

On September 11, 2026, the Ministry of Health and Family Welfare reported that more than 80 lakh HPV vaccine doses had been administered under the nationwide campaign.

According to the government update:

  • Gujarat, Uttar Pradesh, Madhya Pradesh and Mizoram achieved 100% coverage of their identified target populations.

  • Bihar, Andhra Pradesh and Assam crossed 90% coverage.

  • Uttar Pradesh recorded more than 22 lakh vaccinations.

  • The U-WIN digital platform supported programme monitoring and identification of coverage gaps.

These developments demonstrate the expanding role of adolescent vaccination in India's cervical cancer prevention strategy.

WHO Reviews Single-Dose Vaccination – October 2026

In October 2026, WHO's Strategic Advisory Group of Experts on Immunization reviewed additional evidence concerning HPV vaccine dosing.

The review strengthened the recommendation for single-dose vaccination and extended the recommended age range up to 30 years. WHO has indicated that a revised position paper is expected in 2027.

This development may influence future vaccination policies and immunisation strategies in different countries.

HPV Vaccine Laws, Regulations and Government Policies in India

HPV vaccination in India is influenced by national immunisation policies, pharmaceutical regulations and public health guidelines.

The Government of India has introduced measures to improve vaccination coverage and strengthen preventive healthcare.

National HPV Vaccination Campaign

The nationwide campaign launched on February 28, 2026, focuses on girls aged 14 years.

Its main features include:

  • Voluntary vaccination with parental or guardian consent.

  • Single-dose Gardasil-4 vaccination under the national campaign.

  • Availability at designated government healthcare facilities.

  • Medical supervision during vaccination.

  • Monitoring and management arrangements for adverse events following immunisation.

The programme is implemented through coordination between the central government, State governments and Union Territories.

Role of CDSCO

The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory authority for pharmaceuticals and vaccines.

It oversees the approval and regulation of relevant medical products under applicable drug laws and regulatory frameworks.

HPV vaccine manufacturers must meet the relevant regulatory and quality requirements before their products can be used in India.

Clinical Trial and Research Regulations

The New Drugs and Clinical Trials Rules, 2019, establish a regulatory framework for clinical trials and new drugs.

These rules include provisions concerning ethics committee registration, clinical trial oversight and participant protection.

The government has also highlighted the importance of scientific review, informed consent and safety monitoring in vaccine-related research.

U-WIN Digital Vaccination Platform

The U-WIN platform supports registration, vaccination records and monitoring under India's immunisation programmes.

Eligible beneficiaries can use the platform for HPV vaccination registration according to applicable programme procedures. Parents can also seek assistance from healthcare workers or enquire about on-site registration.

Helpful Tools and Resources for HPV Vaccine Information

Reliable information is important when making decisions about vaccination, cervical cancer prevention and reproductive health.

The following resources can help individuals, parents and healthcare professionals understand HPV vaccination.

Resource

Purpose

World Health Organization (WHO)

International HPV vaccination recommendations and research

Ministry of Health and Family Welfare

Indian vaccination policies and public health updates

U-WIN Portal

Vaccination registration and immunisation records

CDSCO Website

Vaccine approvals and regulatory information

National Health Mission (NHM)

HPV vaccination guidelines and educational materials

ICMR

Medical research and public health information

Additional Information to Explore

  • HPV vaccine safety and possible side effects.

  • Cervical cancer symptoms and risk factors.

  • HPV vaccination schedules for different age groups.

  • Pap smear and HPV DNA screening information.

  • Preventive healthcare guidance for adolescents.

These resources can help readers distinguish medically supported information from common misconceptions.

Frequently Asked Questions About the HPV Vaccine

1. What is the main purpose of the HPV vaccine?

The main purpose of the HPV vaccine is to prevent infections caused by specific human papillomavirus types. It helps reduce the risk of cervical cancer and certain other HPV-related diseases. The vaccine works best when administered before exposure to the virus.

2. At what age should someone receive the HPV vaccine?

The recommended starting age is generally 9–14 years. WHO identifies girls aged 9–14 as the primary target group. However, vaccination recommendations for older adolescents and adults depend on the applicable national guidelines, vaccine type and individual health circumstances.

3. Is the HPV vaccine safe?

HPV vaccines have undergone clinical testing and extensive safety monitoring. Common side effects include temporary pain, redness or swelling at the injection site, mild fever, headache and dizziness. Serious allergic reactions are rare. Medical professionals should assess individuals with previous severe allergic reactions before vaccination.

4. Can the HPV vaccine prevent an existing HPV infection?

No. The HPV vaccine is designed to prevent new infections from specific HPV types. It does not treat an existing infection, remove abnormal cervical cells or cure cervical cancer. People with an existing HPV infection should consult a healthcare professional about appropriate monitoring and treatment.

5. Is cervical cancer screening necessary after HPV vaccination?

Yes. HPV vaccination does not eliminate the need for cervical cancer screening. Vaccines do not protect against every high-risk HPV type, and screening helps identify abnormal cervical changes at an early stage. Women should follow the screening recommendations applicable to their age and medical circumstances.

Conclusion: Understanding the Role of HPV Vaccination in Preventive Healthcare

The HPV vaccine plays an important role in reducing infections associated with cervical cancer and other HPV-related diseases. Early vaccination, accurate health information and regular cervical cancer screening are essential parts of a comprehensive prevention strategy.

Recent developments, including India's nationwide vaccination campaign in February 2026 and WHO's October 2026 recommendations, demonstrate the growing importance of HPV immunisation in public health planning.

Parents, adolescents and adults can benefit from understanding vaccine types, recommended schedules, potential side effects and national immunisation policies.

Although vaccination provides significant protection, it should be combined with appropriate screening and medical guidance. Access to reliable information and informed healthcare decisions can contribute to better long-term health outcomes and stronger cervical cancer prevention efforts.